我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
- SK Life Science will present ten posters at the 2026 American Academy of Neurology Annual Meeting showcasing cenobamate's clinical outcomes, real-world evidence, and pharmacokinetic data across multiple patient populations. - The presentations include new analysis from the "Hope, Hesitancy, and Hard Truths" survey examining communication barriers between epilepsy patients and healthcare providers, building on findings first shared during National Epilepsy Awareness Month. - Clinical data will cover cenobamate's efficacy in primary generalized tonic-clonic seizures in adults and adolescents, healthcare utilization outcomes, and long-term safety results from multinational populations. - Research findings address critical unmet needs in epilepsy care, where nearly 40% of the 3.4 million Americans with epilepsy do not achieve seizure freedom despite available treatments.
